Data Processing and Analytic Support in the PLCO Cancer Screening Trial
Jerome Mabie(Information Management Services), Philip C. Prorok(National Cancer Institute), Craig Williams(The University of Adelaide), Kelly J. Yu(National Cancer Institute), Tom Riley(National Institutes of Health), Amanda Black(St. Elizabeth's Hospital), Joe Austin, Michael Young(Regeneron (United States)), Josh Rathmell, Pamela M. Marcus(University of Wisconsin Carbone Cancer Center), Heather Rozjabek(Janssen (United States))
Cited by 3
Related Papers
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
|JNCI Journal of the National Cancer Institute|2012|1.1k
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
|Controlled Clinical Trials|2000|1k
Colorectal-Cancer Incidence and Mortality with Screening Flexible Sigmoidoscopy
|New England Journal of Medicine|2012|1k
Selection Criteria for Lung-Cancer Screening
|New England Journal of Medicine|2013|1k